Last updated August 29, 2026
Key finding
38 of 39 participants (97%) achieved an AG <183 mg/dL.
The iLet Bionic Pancreas System was evaluated for its effectiveness in improving glycemia in adults with Type 1 Diabetes, showing significant improvements in average glucose levels and time in range.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The iLet Bionic Pancreas System was evaluated for its effectiveness in improving glycemia in adults with Type 1 Diabetes, showing significant improvements in average glucose levels and time in range.
Improving glycemic control is crucial for individuals with Type 1 Diabetes to reduce the risk of complications. The iLet Bionic Pancreas offers a promising alternative to traditional management strategies, potentially enhancing quality of life and health outcomes for patients.
Sample size was small, limiting generalizability. Effectiveness data were unclear for some outcomes. No long-term follow-up data were provided.
Published in
Publication details and source links for this paper.
Sean MO, Melissa SP, Steven JR, et al. The iLet Bionic Pancreas System Improves Glycemia in Adults with Type 1 Diabetes. Clinical Diabetes : A Publication of the American Diabetes Association. 2025;43(3):388-398. doi:10.2337/cd24-0104
97% of participants achieved AG <183 mg/dL with the iLet Bionic Pancreas.
Average glucose decreased by 10 mg/dL to 145 ± 10 mg/dL with the bionic pancreas.
Time in range increased to 77.5 ± 9.4% during Bionic Pancreas use.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Usual care, iLet Bionic Pancreas system and Average glucose levels measured over 24 hours, Time in range, Daily glucose average, and 2 more.
This study contributes evidence to
Primary intervention
Usual care
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
6
Evidence pairs
642
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
iLet Bionic Pancreas system → Daily glucose average
iLet Bionic Pancreas system → Daily glucose average
iLet Bionic Pancreas system → Percentage of participants achieving average glucose <154 mg/dL
iLet Bionic Pancreas system → Percentage of participants achieving average glucose <154 mg/dL
iLet Bionic Pancreas system → Percentage of participants achieving average glucose <183 mg/dL
iLet Bionic Pancreas system → Percentage of participants achieving average glucose <183 mg/dL
Usual care → Average glucose levels measured over 24 hours
Usual care → Average glucose levels measured over 24 hours
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Usual care and CGM Time in Range, iLet Bionic Pancreas system and Daily glucose average.
This study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Devices & Technology
Curated evidence collections and hubs this study is part of.
All studies measuring CGM Time in Range
Measures CGM Time in Range as a key outcome.
All studies on Usual care
Contributes to Usual care evidence base.
All studies measuring Daily glucose average
Measures Daily glucose average as a key outcome.
All studies on iLet Bionic Pancreas system
Contributes to iLet Bionic Pancreas system evidence base.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
1 results
3 results
1 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Current evidence does not show a clear benefit of Usual care for time in range.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Strong | EvidenceScore™ 78.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
iLet Bionic Pancreas system appears to improve daily glucose average.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Daily glucose average
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
iLet Bionic Pancreas system appears to improve percentage of participants achieving average glucose <154 mg/dl.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of participants achieving average glucose <154 mg/dL
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
iLet Bionic Pancreas system appears to improve percentage of participants achieving average glucose <183 mg/dl.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of participants achieving average glucose <183 mg/dL
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
